arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

CNBX Pharmaceuticals Inc.

CNBX
Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
70 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
54
Health
Fair
Bullish
auto_awesome

Analytical Summary

CNBX Pharmaceuticals Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC 4.8%
FCF / Share $-0.00
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.05
info Valuation on last close.

70-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-154.16K
↓ -158.1%
Operating Margin Operating profit as % of sales
-192.2%
↓ -19.0%
FCF / Share Free cash flow per share
$-0.00
↓ -10.2%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
75
Financial Health
34
Cash Quality
42

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 21 years · 70 quarters